U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sobieraj DM, Coleman CI, Tongbram V, et al. Venous Thromboembolism Prophylaxis in Orthopedic Surgery [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Mar. (Comparative Effectiveness Reviews, No. 49.)

Cover
  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Venous Thromboembolism Prophylaxis in Orthopedic Surgery

Venous Thromboembolism Prophylaxis in Orthopedic Surgery [Internet].

Show details

Appendix FAdditional Evidence Tables

Table 12. Final health outcomes in randomized controlled trials evaluating patients who had major orthopedic surgery (MS Word, 126K)

Table 13. Final health outcomes in randomized controlled trials evaluating nonmajor orthopedic surgery (MS Word, 98K)

Table 14. Final health outcomes in observational studies evaluating venous thromboembolism prophylaxis in major orthopedic surgery (MS Word, 100K)

Table 15. Intermediate health outcomes from randomized controlled trials evaluating patients who had major orthopedic surgery (MS Word, 120K)

Table 16. Intermediate health outcomes in randomized controlled trials evaluating patients who had nonmajor orthopedic surgery (MS Word, 97K)

Table 17. Intermediate health outcomes in observational studies evaluating venous thromboembolism prophylaxis in major orthopedic surgery (MS Word, 98K)

Table 18. Major and minor bleeding from randomized controlled trials evaluating patients who had major orthopedic surgery (MS Word, 120K)

Table 19. Bleeding outcomes in randomized controlled trials evaluating patients who had nonmajor orthopedic surgery (MS Word, 98K)

Table 20. Major and minor bleeding outcomes in observational studies evaluating venous thromboembolism prophylaxis in major orthopedic surgery (MS Word, 99K)

Table 21. Adverse outcomes from randomized controlled trials evaluating patients who had major orthopedic surgery (MS Word, 124K)

Table 22. Adverse outcomes in randomized controlled trials evaluating nonmajor orthopedic suregery (MS Word, 98K)

Table 23. Additional adverse events in observational studies evaluating venous thromboembolism prophylaxis in major orthopedic surgery (MS Word, 99K)

References for Evidence Tables

  1. Barden B, Kröger K, Löer F. Intraoperative Dopplersonography of the femoral vein for maintenance of venous flow in a hip endoprosthesis. Unfallchirurg. 2001;104:138–42. [PubMed: 11471407]
  2. Farag E, Dilger J, Brooks P, et al. Epidural analgesia improves early rehabilitation after total knee replacement. J Clin Anesth. 2005;17:281–5. [PubMed: 15950853]
  3. Jorgensen LN, Rasmussen LS, Nielsen PT, et al. Antithrombotic efficacy of continuous extradural analgesia after knee replacement. Br J Anaesth. 1991;66:8–12. [PubMed: 1997063]
  4. Kim YH, Oh SH, Kim JS. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. A prospective and randomised clinical study. J Bone Joint Surg Br. 2003;85:661–5. [PubMed: 12892186]
  5. Laupacis A, Rorabeck C, Bourne R, et al. The frequency of venous thrombosis in cemented and non-cemented hip arthroplasty. J Bone Joint Surg Br. 1996;78:210–2. [PubMed: 8666626]
  6. Levy O, Martinowitz U, Oran A, et al. The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective, randomized, multicenter study. J Bone Joint Surg Am. 1999;81:1580–8. [PubMed: 10565650]
  7. Mitchell D, Friedman RJ, Baker JD 3rd, et al. Prevention of thromboembolic disease following total knee arthroplasty. Epidural versus general anesthesia. Clin Orthop. 1991;(269):109–12. [PubMed: 1864027]
  8. Nielsen PT, Jorgensen LN, Albrecht-Beste E, et al. Lower thrombosis risk with epidural blockade in knee arthroplasty. Acta Orthop Scand. 1990;61:29–31. [PubMed: 2186591]
  9. Pitto RP, Hamer H, Fabiani R, et al. Prophylaxis against fat and bone-marrow embolism during total hip arthroplasty reduces the incidence of postoperative deep-vein thrombosis: a controlled, randomized clinical trial. J Bone Joint Surg Am. 2002;84-A:39–48. [PubMed: 11792778]
  10. Planes A, Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999;81:22–5. [PubMed: 10348714]
  11. Thorey F, Stukenborg-Colsman C, Windhagen H, et al. The effect of tourniquet release timing on perioperative blood loss in simultaneous bilateral cemented total knee arthroplasty: A prospective randomized study. Technology and Health Care. 2008;16:85–92. [PubMed: 18487854]
  12. Westrich GH, Winiarsky R, Betsy M, et al. Effect on deep venous thrombosis with flexion during total knee arthroplasty. HSS Journal. 2006;2:148–53. [PMC free article: PMC2488169] [PubMed: 18751828]
  13. Williams-Russo P, Sharrock NE, Haas SB, et al. Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement. Clin Orthop. 1996:199–208. [PubMed: 8895639]
  14. Abdel-Salam A, Eyres K. Effects of tourniquet during total knee arthroplasty: A prospective randomised study. J Bone Joint Surg. 1995;77-B:250–3. [PubMed: 7706340]
  15. McKenzie PJ, Wishart HY, Gray I, et al. Effects of anaesthetic technique on deep vein thrombosis. A comparison of subarachnoid and general anaesthesia. Br J Anaesth. 1985;57:853–7. [PubMed: 4027101]
  16. Wakankar HM, Nicholl JE, Koka R, et al. The tourniquet in total knee arthroplasty. J Bone Joint Surg. 1999;81-B:30–3. [PubMed: 10067997]
  17. Modig J, Hjelmstedt A, Sahlstedt B, et al. Comparative influences of epidural and general anaesthesia on deep venous thrombosis and pulmonary embolism after total hip replacement. Acta Chir Scand. 1981;147:125–30. [PubMed: 7324741]
  18. Alfaro MJ, Paramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost. 1986;56:53–6. [PubMed: 3535158]
  19. Chin PL, Amin MS, Yang KY, et al. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. J Orthop Surg. 2009;17:1–5. [PubMed: 19398783]
  20. Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after total hip replacement. J Bone Joint Surg Br. 1992;74:45–9. [PubMed: 1732264]
  21. Fuji T, Ochi T, Niwa S, et al. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci. 2008;13:442–51. [PubMed: 18843459]
  22. Jorgensen PS, Knudsen JB, Broeng L, et al. [[The thromboprophylactic effect of low molecular weight heparin (Fragmin) in hip fracture surgery. A placebo controlled trial]]. Ugeskr Laeger. 1993;155:706–8. [PubMed: 8384388]
  23. Jorgensen PS, Knudsen JB, Broeng L, et al. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. Clin Orthop. 1992;(278):95–100. [PubMed: 1314147]
  24. Kim YH, Choi IY, Park MR, et al. Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran in Korean patients undergoing total hip replacement. A randomized controlled trial. Int Orthop. 1998;22:6–10. [PMC free article: PMC3619654] [PubMed: 9549575]
  25. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthop Scand. 1991;62:33–8. [PubMed: 1848385]
  26. McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J. 1980;280:514–7. [PMC free article: PMC1601413] [PubMed: 6989432]
  27. Samama CM, Clergue F, Barre J, et al. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Br J Anaesth. 1997;78:660–5. [PubMed: 9215015]
  28. Sorensen JV, Borris LC, Lassen MR, et al. Levels of thrombin--antithrombin-III complex and factor VIII activity in relation to post-operative deep vein thrombosis and influence of prophylaxis with a low-molecular-weight heparin. Blood Coagul Fibrinolysis. 1990;1:389–92. [PubMed: 1966794]
  29. Sorensen JV, Borris LC, Lassen MR, et al. Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis Group. Thromb Res. 1990;59:131–8. [PubMed: 2169077]
  30. Torholm C, Broeng L, Jorgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br. 1991;73:434–8. [PubMed: 1670445]
  31. Turpie AG. Enoxaparin prophylaxis in elective hip surgery. Acta Chir Scand Suppl. 1990;556:103–7. [PubMed: 1963014]
  32. Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925–9. [PubMed: 3531851]
  33. WelinBerger T, Bygdeman S, Mebius C. Deep vein thrombosis following hip surgery. Relation to activated factor X inhibitor activity: effect of heparin and dextran. Acta Orthop Scand. 1982;53:937–45. [PubMed: 6184938]
  34. Wilson NV, Das SK, Kakkar VV, et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System. J Bone Joint Surg Br. 1992;74:50–2. [PubMed: 1732265]
  35. Warwick D, Bannister G, Glew D, et al. Perioperative low-Molecular-Weight Heparin: Is it effective and safe? J Bone Joint Surg. 1995;77-B:715–9. [PubMed: 7559695]
  36. Fuji T, Fuijita S, Ujihira T, et al. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. J Arthroplasty. 2010;25:1267–74. [PubMed: 19854610]
  37. A multicenter, multinational, randomized double-blind comparison study of subcutaneous Org31540/SR90107A versus enoxaparin 40 mg o.d. in the prevention of deep vein thrombosis and symptomatic pulmonary embolism in hip fracture surgery. (PENTHIFRA). GlaxoSmithKline Clinical Trial Register. 2005. Study No: EFC2698.
  38. Avikainen V, von Bonsdorff H, Partio E, et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Ann Chir Gynaecol. 1995;84:85–90. [PubMed: 7645915]
  39. Bailey JP, Kruger MP, Solano FX, et al. Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J Arthroplasty. 1991;6:S29–35. [PubMed: 1774568]
  40. Barre J, Pfister G, Potron G, et al. [[Comparison of the efficacy and tolerance of Kabi 2165 and standard heparin in the prevention of deep venous thrombosis in total hip prosthesis]]. J Mal Vasc. 1987;12:90–5. [PubMed: 2834500]
  41. Bonneux IM, Bellemans J, Fabry G. Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin. Knee. 2006;13:118–21. [PubMed: 16387501]
  42. Cofrancesco E, Cortellaro M, Corradi A, et al. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery. Thromb Haemost. 1997;77:267–9. [PubMed: 9157579]
  43. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999;81:932–40. [PubMed: 10428124]
  44. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 1994;76:3–14. [PubMed: 8288662]
  45. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop. 1995;(321):19–27. [PubMed: 7497668]
  46. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis. 1989;19:5–12. [PubMed: 2537787]
  47. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298–304. [PubMed: 11794148]
  48. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–11. [PubMed: 15634273]
  49. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–85. (a) [PubMed: 17764540]
  50. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–56. (b) [PubMed: 17869635]
  51. Eriksson BI, Ekman S, Kalebo P, et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347:635–9. [PubMed: 8596376]
  52. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79:326–33. (a) [PubMed: 9070519]
  53. Eriksson BI, Eriksson E, Risberg B. Impaired fibrinolysis and postoperative thromboembolism in orthopedic patients. Thromb Res. 1991;62:55–64. [PubMed: 1853306]
  54. Eriksson BI, Kalebo P, Anthymyr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991;73:484–93. [PubMed: 2013587]
  55. Eriksson BI, Kalebo P, Risberg B. Clinical experience of a low molecular weight heparin (Fragmin) in the prevention of thromboembolism after total hip replacement. Semin Thromb Hemost. 1993;19:122–7. [PubMed: 8395714]
  56. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329–35. (b) [PubMed: 9358126]
  57. Fauno P, Suomalainen O, Rehnberg V, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am. 1994;76:1814–8. [PubMed: 7989386]
  58. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am. 2001;83-A:900–6. [PubMed: 11407799]
  59. Francis CW, Pellegrini VD Jr, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911–5. [PubMed: 1583760]
  60. Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997;79:1365–72. [PubMed: 9314399]
  61. Greinacher A, Eichler P, Albrecht D, et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood. 2003;101:2617–9. [PubMed: 12393696]
  62. Haas SB, Insall JN, Scuderi GR, et al. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Am. 1990;72:27–31. [PubMed: 2404020]
  63. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1370–6. [PubMed: 8413432]
  64. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients a double-blind, randomized comparisons. Arch Intern Med. 2000;160:2199–207. [PubMed: 10904464]
  65. Kennedy JG, Soffe KE, Rogers BW, et al. Deep vein thrombosis prophylaxis in hip fractures: A comparison of the arteriovenous impulse system and aspirin. Journal of Trauma - Injury, Infection and Critical Care. 2000;48:268–72. [PubMed: 10697085]
  66. Lassen M, Bauer K, Eriksson B, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715–20. [PubMed: 12049858]
  67. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368–75. [PubMed: 17868430]
  68. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med. 1996;124:619–26. [PubMed: 8607589]
  69. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545–51. [PubMed: 1848054]
  70. Levine MN, Planes A, Hirsh J, et al. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989;62:940–4. [PubMed: 2556813]
  71. Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop. 1996:251–8. [PubMed: 8595765]
  72. Menzin J, Richner R, Huse D, et al. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother. 1994;28:271–5. [PubMed: 8173149]
  73. Paiement G, Wessinger SJ, Waltman AC, et al. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty. 1987;2:23–6. [PubMed: 3572408]
  74. Planes A, Vochelle N, Mazas F, et al. [[Double-blind randomized comparative study of enoxaparin and standard heparin in the prevention of thromboembolic disease during insertion of total hip replacement]]. Rev Med Interne. 1988;9:327–33. [PubMed: 2841742]
  75. Planes A, Vochelle N, Mazas F, et al. [The use of enoxaparine in preventing deep venous thrombosis following total hip prosthesis. Randomized multicenter prospective trial] Rev Chir Orthop Reparatrice Appar Mot. 1988;74:215–8. [PubMed: 2852830]
  76. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988;60:407–10. [PubMed: 2853459]
  77. RE-MOBILIZE Writing Committee. Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9. [PubMed: 18534438]
  78. Santori FS, Vitullo A, Stopponi M, et al. Prophylaxis against deep-vein thrombosis in total hip replacement. Comparison of heparin and foot impulse pump. J Bone Joint Surg Br. 1994;76:579–83. [PubMed: 8027144]
  79. Schwartsmann CR, Cavalieri CR, Drumond SN, et al. Randomized, comparative, open study to assess the efficacy and safety of enoxaparin compared with unfractionated heparin in the prophylaxis of venous thromboembolism in patients undergoing total hip arthroplasty. Revista Brasileira De Ortopedia. 1996;31:797–808.
  80. Senaran H, Acaroglu E, Ozdemir HM, et al. Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients. Arch Orthop Trauma Surg. 2006;126:1–5. [PubMed: 16333632]
  81. Stone MH, Limb D, Campbell P, et al. A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study. Int Orthop. 1996;20:367–9. [PubMed: 9049766]
  82. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359:1721–6. [PubMed: 12049860]
  83. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518–24. [PubMed: 14609790]
  84. Warwick D, Harrison J, Glew D, et al. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am. 1998;80:1158–66. [PubMed: 9730125]
  85. Warwick D, Harrison J, Whitehouse S, et al. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br. 2002;84:344–50. [PubMed: 12002490]
  86. Warkentin T, Levine M, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5. [PubMed: 7715641]
  87. Rader CP, Kramer C, König A, et al. Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty. J arthroplasty. 1998;13:180–5. [PubMed: 9526211]
  88. Monreal M, Lafoz E, Navarro A, et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma. 1989;29:873–5. [PubMed: 2544742]
  89. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305–10. [PubMed: 11794149]
  90. Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement. [Oct. 22, 2010]. Available at: http:​//clinicaltrials​.gov/ct2/show/NCT00152971.
  91. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group. Haemostasis. 1999;29:310–7. [PubMed: 10844404]
  92. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol. 1999;104:230–40. [PubMed: 10050702]
  93. Lachiewicz PF, Kelley SS, Haden LR. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. A prospective, randomised study. (Series B).Journal of Bone and Joint Surgery. 2004;86:1137–41. [PubMed: 15568526]
  94. Planes A. An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement. Semin Thromb Hemost. 2000;26:57–60. [PubMed: 11011808]
  95. Ryan MG, Westrich GH, Potter HG, et al. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg Am. 2002;84-A:1998–2004. [PubMed: 12429761]
  96. Silbersack Y, Taute BM, Hein W, et al. Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br. 2004;86:809–12. [PubMed: 15330019]
  97. Edwards JZ, Pulido PA, Ezzet KA, et al. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. J Arthroplasty. 2008;23:1122–7. [PubMed: 18534421]
  98. Lieberman JR, Huo MM, Hanway J, et al. The prevalence of deep venous thrombosis after total hip arthroplasty with hypotensive epidural anesthesia. J Bone Joint Surg Am. 1994;76:341–8. [PubMed: 8126039]
  99. Westrich GH, Sculco TP. Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. J Bone Joint Surg Am. 1996;78:826–34. [PubMed: 8666599]
  100. Woolson ST, Watt JM. Intermittent pneumatic compression to prevent proximal deep venous thrombosis during and after total hip replacement. A prospective, randomized study of compression alone, compression and aspirin, and compression and low-dose warfarin. J Bone Joint Surg Am. 1991;73:507–12. [PubMed: 2013589]
  101. Andersen BS. Postoperative activation of the haemostatic system--influence of prolonged thromboprophylaxis in patients undergoing total hip arthroplasty. Haemostasis. 1997;27:219–27. [PubMed: 9690480]
  102. Arnesen H, Dahl OE, Aspelin T, et al. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost. 2003;1:971–5. [PubMed: 12871363]
  103. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696–700. [PubMed: 8703168]
  104. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001;83-A:336–45. [PubMed: 11263636]
  105. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997;77:26–31. [PubMed: 9031444]
  106. Dahl OE, Aspelin T, Arnesen H, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res. 1995;80:299–306. [PubMed: 8585042]
  107. Eriksson BI, Lassen MR, et al. PENTasaccharide in HIp-FRActure Surgery Plus,Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163:1337–42. [PubMed: 12796070]
  108. Manganelli D, Pazzagli M, Mazzantini D, et al. Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration. 1998;65:369–74. [PubMed: 9782219]
  109. Nilsson PE, Bergqvist D, Benoni G, et al. The postdischarge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. Orthopedics. 1997;20:22–5. [PubMed: 9048404]
  110. Planes A, Vochelle N. The post-hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics. 1997;20:18–21. [PubMed: 9048403]
  111. Planes A, Vochelle N, Darmon JY. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the French study--venographic outcome at 35 days. Chest. 1998;114:125S–9S. [PubMed: 9726707]
  112. Planes A, Vochelle N, Darmon JY, et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. Drugs. 1996;52:47–54. [PubMed: 9042560]
  113. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224–8. [PubMed: 8684199]
  114. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 2002;162:1966–71. [PubMed: 12230419]
  115. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med. 1989;149:771–4. [PubMed: 2650646]
  116. Kalodiki EP, Hoppensteadt DA, Nicolaides AN, et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. Int Angiol. 1996;15:162–8. [PubMed: 8803642]
  117. Stannard JP, Harris RM, Bucknell AL, et al. Prophylaxis of deep venous thrombosis after total hip arthroplasty by using intermittent compression of the plantar venous plexus. Am J Orthop. 1996;25:127–34. [PubMed: 8640382]
  118. Dorr LD, Gendelman V, Maheshwari AV, et al. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am. 2007;89:2648–57. [PubMed: 18056497]
  119. Gandhi R, Razak F, Tso P, et al. Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty. J Rheumatol. 2009;36:2298–301. [PubMed: 19684153]
  120. Leizorovicz A, Turpie AGG, Cohen AT, et al. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study. Journal of Thrombosis and Haemostasis. 2005;3:28–34. [PubMed: 15634263]
  121. Lemos MJ, Sutton D, Hozack WJ, et al. Pulmonary embolism in total hip and knee arthroplasty. Risk factors in patients on warfarin prophylaxis and analysis of the prothrombin time as an indicator of warfarin's prophylactic effect. Clin Orthop. 1992:158–63. [PubMed: 1516307]
  122. McNamara I, Sharma A, Prevost T, et al. Symptomatic venous thromboembolism following a hip fracture. Acta Orthop. 2009;80:687–92. [PMC free article: PMC2823318] [PubMed: 19968601]
  123. Ryan DH, Crowther MA, Ginsberg JS, et al. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med. 1998;128:270–6. [PubMed: 9471929]
  124. Haas SB, Tribus CB, Insall JN, et al. The significance of calf thrombi after total knee arthroplasty. J Bone Joint Surg Br. 1992;74:799–802. [PubMed: 1447236]
  125. Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am. 1997;79:319–25. [PubMed: 9070518]
  126. Cusick LA, Beverland DE. The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. J Bone Joint Surg Br. 2009;91:645–8. [PubMed: 19407300]
  127. Happe LE, Farrelly EM, Stanford RH, et al. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries. J Thromb Thrombolysis. 2008;26:125–31. [PubMed: 18034323]
  128. Sachs RA, Smith JH, Kuney M, et al. Does anticoagulation do more harm than good? A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty. J Arthroplasty. 2003;18:389–95. [PubMed: 12820078]
  129. Shorr AF, Kwong LM, Sarnes M, et al. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. Thromb Res. 2007;121:17–24. [PubMed: 17449088]
  130. Bozic KJ, Vail TP, Pekow PS, et al. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25:1053–60. [PMC free article: PMC4142798] [PubMed: 19679434]
  131. Froimson MI, Murray TG, Fazekas AF. Venous thromboembolic disease reduction with a portable pneumatic compression device. J Arthroplasty. 2009;24:310–6. [PubMed: 18534456]
  132. Gerkens S, Crott R, Closon MC, et al. Comparing the quality of care across Belgian hospitals from medical basic datasets: the case of thromboembolism prophylaxis after major orthopaedic surgery. J Eval Clin Pract. 2010;16:685–692. [PubMed: 20545808]
  133. Yokote R, Matsubara M, Hirasawa, et al. Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? J Bone Joint Surg (Br). 2011;93-B:251–256. [PubMed: 21282767]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (6.4M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...